Nicotinic Acetylcholine Receptors and Imaging

Author: Gundisch, D.

Source: Current Pharmaceutical Design, Volume 6, Number 11, 1 July 2000 , pp. 1143-1157(15)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

In vivo imaging techniques like positron emission tomography (PET) and single photon emission computed tomography (SPECT) offer the possibility to monitor human central nicotinic acetylcholine receptors (nAChRs) in a variety of central nervous system disorders. In the past, the only available PET radiotracer for imaging nAChRs in the human brain, ( 11 C)-(-)-nicotine, suffered from a spectrum of not suitable properties for in vivo imaging. Current efforts are focused on the development of new, highly specific and highly selective radioligands based on different structural classes (e.g. nicotine, epibatidine, 3-pyridyl ether analogues) for central nAChRs. The most promising compounds are halogenated 3-pyridyl ether compounds for imaging a4beta2 nAChRs. But there is still a lack for radiotracers for other subtypes of nicotinic acetylcholine receptors being a promising area of interest.

Keywords: Nicotinic acetylcholine receptors; SPECT; Positron emission tomography; Emission computerized tomography; Human nAChRs; CNS diseases; Nicotine; Spect radioligands; Epibatidine; PET

Document Type: Review article

DOI: 10.2174/1381612003399879

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy